全文获取类型
收费全文 | 152465篇 |
免费 | 10936篇 |
国内免费 | 705篇 |
专业分类
耳鼻咽喉 | 1804篇 |
儿科学 | 3716篇 |
妇产科学 | 2660篇 |
基础医学 | 19665篇 |
口腔科学 | 3365篇 |
临床医学 | 15038篇 |
内科学 | 31311篇 |
皮肤病学 | 2006篇 |
神经病学 | 13550篇 |
特种医学 | 6429篇 |
外科学 | 24418篇 |
综合类 | 2107篇 |
现状与发展 | 1篇 |
一般理论 | 189篇 |
预防医学 | 13520篇 |
眼科学 | 3390篇 |
药学 | 10612篇 |
2篇 | |
中国医学 | 197篇 |
肿瘤学 | 10126篇 |
出版年
2023年 | 728篇 |
2022年 | 1248篇 |
2021年 | 3054篇 |
2020年 | 1753篇 |
2019年 | 2785篇 |
2018年 | 3367篇 |
2017年 | 2451篇 |
2016年 | 2605篇 |
2015年 | 3195篇 |
2014年 | 4668篇 |
2013年 | 6834篇 |
2012年 | 10144篇 |
2011年 | 10731篇 |
2010年 | 6008篇 |
2009年 | 5521篇 |
2008年 | 9469篇 |
2007年 | 10128篇 |
2006年 | 9549篇 |
2005年 | 9639篇 |
2004年 | 9251篇 |
2003年 | 8633篇 |
2002年 | 8297篇 |
2001年 | 1554篇 |
2000年 | 1314篇 |
1999年 | 1619篇 |
1998年 | 1768篇 |
1997年 | 1414篇 |
1996年 | 1338篇 |
1995年 | 1284篇 |
1994年 | 1092篇 |
1993年 | 1064篇 |
1992年 | 951篇 |
1991年 | 979篇 |
1990年 | 858篇 |
1989年 | 819篇 |
1988年 | 842篇 |
1987年 | 832篇 |
1986年 | 827篇 |
1985年 | 915篇 |
1984年 | 998篇 |
1983年 | 927篇 |
1982年 | 1191篇 |
1981年 | 1202篇 |
1980年 | 1010篇 |
1979年 | 718篇 |
1978年 | 725篇 |
1977年 | 655篇 |
1976年 | 567篇 |
1975年 | 508篇 |
1974年 | 507篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
151.
152.
153.
Molecular determinants of cetuximab efficacy. 总被引:17,自引:0,他引:17
Daniel Vallb?hmer Wu Zhang Michael Gordon Dong Yun Yang Jim Yun Oliver A Press Katrin E Rhodes Andy E Sherrod Syma Iqbal Kathleen D Danenberg Susan Groshen Heinz-Josef Lenz 《Journal of clinical oncology》2005,23(15):3536-3544
PURPOSE: To investigate whether mRNA expression levels of cyclin D1 (CCND1), cyclooxygenase 2 (Cox-2), epidermal growth factor receptor (EGFR), interleukin 8 (IL-8), and vascular endothelial growth factor (VEGF), all members of the EGFR signaling pathway, are associated with clinical outcome in patients with EGFR-expressing metastatic colorectal cancer (CRC) treated with cetuximab. PATIENTS AND METHODS: Thirty-nine patients with metastatic CRC, refractory to both irinotecan and oxaliplatin, were enrolled on IMCL-0144 and treated with single-agent cetuximab. The intratumoral mRNA levels of CCND1, Cox-2, EGFR, IL-8, and VEGF were assessed from paraffin-embedded tissue samples using laser-capture microdissection and quantitative real-time polymerase chain reaction. RESULTS: There were 21 women and 18 men with a median age of 64 years (range, 35 to 83 years). Higher gene expression levels of VEGF were associated with resistance to cetuximab (P = .038; Kruskal-Wallis test). The combination of low gene expression levels of Cox-2, EGFR, and IL-8 was significantly associated with overall survival (13.5 v 2.3 months; P = .028; log-rank test). Both findings were independent of skin toxicity that was itself significantly correlated to survival. Patients with a lower mRNA amount of EGFR had a longer overall survival compared with patients that had a higher mRNA amount (7.3 v 2.2 months; P = .09; log-rank test). Patients with lower expression of Cox-2 had a significantly higher rate of grade 2 to 3 skin reactions under cetuximab treatment. CONCLUSION: This pilot study suggests that gene expression levels of Cox-2, EGFR, IL-8, and VEGF in patients with metastatic CRC may be useful markers of clinical outcome in single-agent cetuximab treatment. 相似文献
154.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
155.
156.
157.
Lidong Zhang James E Littlejohn Yu Cui Xiaobo Cao Chander Peddaboina W Roy Smythe 《Molecular cancer》2010,9(1):110
Background
Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy. 相似文献158.
159.
160.